Allergen inactivator and topical skin preparation containing same

Plant extracts from the American red maple tree and Gambhir tree are used to inactivate allergens topically, addressing the limitations of existing treatments by preventing allergic reactions and reducing symptoms without side effects.

JP7577295B2Active Publication Date: 2024-11-05ANDS CORP
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
JP2020074801
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-04-20
Publication Date
2024-11-05
Estimated Expiration
2040-04-20

AI Technical Summary

Technical Problem

Existing anti-allergic drugs and steroids fail to completely suppress allergic symptoms and can cause side effects, while existing allergen inactivators are limited in variety and effectiveness.

Method used

Utilizing plant extracts from the American red maple tree and Gambhir tree as allergen inactivators, applied topically to inactivate allergens by coating or denaturing their recognition sites, thereby preventing antibody interaction and subsequent allergic reactions.

Benefits of technology

The plant extracts effectively inactivate allergens, reducing the occurrence of allergic symptoms such as sneezing, runny nose, and itchy eyes by preventing allergen-antibody binding, particularly effective against pollen-induced type I allergic diseases like hay fever.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577295000001
    Figure 0007577295000001
Patent Text Reader

Abstract

To provide an allergen inactivating agent comprising a plant extract as an active ingredient.SOLUTION: The allergen inactivating agent of the present invention comprises an extract from one or two plants selected from red maple and Gambir as an active ingredient and makes an antibody unable to recognize an allergen by covering or denaturing the recognition site of the allergen with the antibody. In the present invention, it may be used as a skin external preparation containing an allergen inactivating agent. The amount of the allergen inactivating agent to be added to the external skin preparation may be 0.001 to 2.0% by mass.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an allergen inactivating agent and an external skin preparation containing the same. [Background technology]

[0002] At present, due to the worsening of environmental conditions, changes in lifestyle, and increased stress accompanying the complexity of social life, the number of people suffering from allergic diseases such as bronchial asthma, hay fever, allergic rhinitis, atopic dermatitis, and drugs is increasing. Allergy is a phenomenon in which an antigen-antibody reaction damages tissues, and is classified into four types, from type I (immediate type) to type IV (delayed type), depending on the mechanism of onset. Symptoms medically classified as type I allergy include hay fever, atopic dermatitis, and bronchial asthma. In particular, the prevalence of hay fever is increasing year by year, and it is said that 25% of the Japanese population suffers from hay fever.

[0003] It is estimated that about 70% of hay fever sufferers suffer from cedar pollen allergy. This is because artificial cedar forests are so large that they account for 18% of the nation's forests and 12% of Japan's land area. Due to the effects of global warming in recent years, the amount of cedar pollen released into the air is expected to increase.

[0004] It has been revealed that allergic reactions such as hay fever occur through the following mechanism. When allergens such as pollen adhere to the conjunctiva or nasal mucosa and enter the body, the allergens are phagocytosed and decomposed by antigen-presenting cells. After being phagocytosed and decomposed, information about the allergen is sent from the antigen-presenting cells to B cells via T cells. The B cells that receive the information produce antibodies against the allergen, and the produced antibodies bind to mast cells. Then, when the allergen enters the body again, the mast cells that have bound to the antibodies recognize the allergen through the antibodies and release histamine and leukotrienes. Histamine, leukotrienes, etc. cause allergic symptoms such as sneezing, runny nose, stuffy nose, itchy eyes, and watery eyes.

[0005] Drugs that suppress and improve such allergic symptoms include antiallergic drugs such as antihistamines, anti-leukotriene drugs, chemical mediator release inhibitors, etc. In addition, steroid drugs that reduce inflammation by weakening immune responsiveness have also been developed.

[0006] The above-mentioned antiallergic drugs and steroids are mainly used as treatments for allergic diseases, but they are unable to completely suppress allergic symptoms, and increasing the dosage to improve efficacy can lead to problems such as side effects.

[0007] Therefore, in order to reduce excessive dosing of therapeutic drugs such as allergy drugs and steroid drugs, various antiallergic drugs have been provided for use as supplements to enhance the therapeutic effects of allergic diseases or to alleviate allergic symptoms. Many of these supplemental antiallergic drugs are made from plants. Known examples of plant-derived supplemental antiallergic drugs include tea leaf extracts (see Patent Document 1), raspberry and / or luohan fruit extracts (see Patent Document 2), rose extracts (see Patent Document 3), and plant extracts such as Hypericum perforatum (see Patent Document 4).

[0008] As mentioned above, symptomatic treatment using antiallergic drugs or steroid drugs is common to suppress allergic symptoms, and there are also supplementary antiallergic drugs that are used to enhance the therapeutic effect of allergic diseases or to alleviate allergic symptoms. In addition, avoiding contact with allergens is also an effective method of suppressing allergic symptoms. For example, in hay fever, avoiding contact with allergens by using masks, glasses, etc. is a simple and effective method of suppressing allergic symptoms.

[0009] Furthermore, in recent years, in addition to the above-mentioned methods, techniques for deactivating allergens that cause allergies have also been developed. One example is a method using an allergen inactivating agent that inactivates allergens so that antibodies cannot recognize them. This is a technique in which the site in the allergen that is recognized by an antibody is covered or denatured with an allergen inactivating agent, making it impossible for the antibody to recognize the allergen. Even if an allergen inactivated by the above-mentioned method enters the body, the antibody will not recognize the allergen. Therefore, histamine and the like are not released, and subsequent allergic symptoms such as a runny nose can be prevented. Plant extracts such as agrimony, hypericum, black tea, and salacia have been provided as allergen inactivating agents (Patent Documents 5 to 7).

[0010] In recent years, diversification of consumer preferences has led to a demand for various plant-derived raw materials, and various plant-derived raw materials have been provided to satisfy consumer demands. Allergen inactivators are no exception, and there is a need and demand to find more plant-derived allergen inactivators. [Prior art documents] [Patent documents]

[0011] [Patent Document 1] Patent Publication No. 3-258726 [Patent Document 2] Patent Publication No. 10-53532 [Patent Document 3] JP 11-180880 [Patent Document 4] Patent Publication No. 2004-175744 [Patent Document 5] Patent Publication No. 2006-143700 [Patent Document 6] Patent Publication No. 2008-174529 [Patent Document 7] Patent Publication No. 2009-155268 Summary of the Invention [Problem to be solved by the invention]

[0012] In view of the above circumstances, the object of the present invention is to find a new plant extract having an allergen inactivating effect, and to provide an allergen inactivating agent utilizing the same, and an external preparation for skin containing the same. [Means for solving the problem]

[0013] (1) A plant extract containing one or two types of plant extracts selected from red maple and gambir tree as active ingredients. 、 The blending amount of the plant extract is 0.001 to 2.0% by mass, It is applied to the skin, Targeting pollen Allergen inactivator. (2) The allergen inactivating agent according to (1), wherein the application site of the allergen inactivating agent is the skin surrounding a mucous membrane. Effect of the Invention

[0014] According to an embodiment of the present invention, it is possible to provide an allergen inactivating agent and an external skin preparation containing the same. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] An embodiment of the present invention will be described below.

[0016] "Allergen inactivation agent" The allergen inactivating agent in the present invention refers to a plant extract having an effect of inactivating an allergen. Here, the effect of inactivating an allergen refers to the effect of coating or denaturing the three-dimensional structure of the recognition site of an allergen with an antibody, thereby making it impossible for the antibody to recognize the allergen.

[0017] The plant extract of the present invention has the effect of inactivating allergens, and can therefore be used as an active ingredient of an allergen inactivator. Due to the effect of inactivating allergens, even if the inactivated allergens enter the human body, they do not react with antibodies, and various allergic symptoms such as sneezing, runny nose, stuffy nose, itchy eyes, watery eyes, etc. can be suppressed.

[0018] The allergen inactivating agent of the present invention is effective for inactivating allergens that cause type I allergic diseases, and is particularly preferably used for suppressing allergic symptoms caused by pollen as an allergen.

[0019] Therefore, the main application of the allergen inactivating agent of the present invention is type I allergic diseases, more specifically, hay fever caused by pollen as an allergen.

[0020] The type of pollen is not particularly limited as long as it is pollen that has the effect of causing type I allergic diseases, and examples include cedar pollen, cypress pollen, ragweed pollen, and orchard grass pollen, and the allergen inactivating agent of the present invention is particularly effective against cedar pollen.

[0021] The plant extract in the present invention refers to an extract obtained by extracting any part of a plant as an extraction raw material with an extraction solvent.

[0022] The extraction solvent used in the present invention is not particularly limited, but may be, for example, one or a combination of two or more of lower alcohols such as ethanol, polyhydric alcohols such as glycerin, propylene glycol, 1,3-butylene glycol, and water.

[0023] The extraction process is not particularly limited as long as the soluble components contained in the extraction raw material can be dissolved in the extraction solvent, and can be performed according to a conventional method. A preferred extraction process is, for example, a method in which a 50% (v / v) aqueous ethanol solution is used as the extraction solvent, extraction is performed at room temperature for 1 to 5 days, and then filtration is performed. The plant extract obtained by the extraction process may be appropriately subjected to treatments such as dilution, concentration, drying, purification, etc. according to conventional methods to obtain a diluted or concentrated solution of the plant extract, a dried product of the extract, or a crude or purified product thereof.

[0024] In this case, the plant extract can be purified by, for example, treatment with activated carbon, treatment with an adsorption resin, treatment with an ion exchange resin, or the like.

[0025] The red maple (scientific name: Acer rubrum) used in Example 1 of the present invention is a cold-resistant deciduous broadleaf tall tree of the maple family, maple genus, native to eastern North America, in the order Sapindales. Also known as red maple and red maple. The part used as the extraction raw material is the bark.

[0026] The gambir tree (scientific name: Uncaria gambir) used in Example 2 of the present invention is a creeping evergreen shrub of the family Rubiaceae, order Rubiaceae, native to Southeast Asia. Also known as gambir. The parts used as the raw material for extraction are the leaves and young branches.

[0027] The Rubus suavissimus used in Comparative Example 1 is a deciduous shrub of the Rubus genus in the family Rosaceae, order Rosales, native to Asia. Another name for it is Tenyokenkoushi. The part used as the raw material for extraction is the leaves.

[0028] The honeysuckle (scientific name: Lonicera japonica) used in Comparative Example 2 is an evergreen climbing shrub native to Japan and East Asia, belonging to the family Caprifoliaceae, order Dipodium, and the genus Honeysuckle. Also known as Lonicera japonica. The parts used as the raw material for extraction are the leaves or stems.

[0029] The European hawthorn (scientific name: Crataegus oxyacantha) used in Comparative Example 3 is a deciduous shrub native to Europe belonging to the family Rosaceae, order Rosales. Also known as Hawthorn. The part used as the raw material for extraction is the fruit.

[0030] The grape (scientific name: Vitis vinifera) used in Comparative Example 4 is a deciduous climbing shrub of the genus Rosa, family Vitaceae, order Vitaceae, native to Western Asia. Also known as Hotou. The part used as the raw material for extraction is the leaves.

[0031] The fennel (scientific name: Foeniculum vulgare) used in Comparative Example 5 is a perennial plant of the genus Foeniculum, family Apiaceae, order Apiales, native to the Mediterranean coast of Europe. Also known as fennel. The part used as the raw material for extraction is the fruit.

[0032] The sage (scientific name: Salvia officinalis) used in Comparative Example 6 is an evergreen shrub or perennial plant of the Lamiaceae family, Lamiales order, native to the Mediterranean coast. Also known as: Salvia officinalis. The part used as the raw material for extraction is the leaves.

[0033] The wild rose (scientific name: Rosa multiflora) used in Comparative Example 7 is a deciduous climbing shrub of the genus Rosa, family Rosaceae, order Rosales, native to Japan. Also known as wild rose. The part used as the raw material for extraction is the fruit.

[0034] The Artemisia princeps used in Comparative Example 8 is a perennial plant of the Artemisia genus, Asteraceae family, native to Asia. Also known as mochigusa. The part used as the raw material for extraction is the leaves.

[0035] The Artemisia capillaris Thunberg used in Comparative Example 9 is a perennial plant of the Artemisia genus, Asteraceae family, and is distributed in Honshu, Shikoku, Kyushu, and Ryukyu in Japan. Also known as Hamayogi and Karakusayogi. The part used as the extraction raw material is the flower head.

[0036] Rosa roxburghii used in Comparative Example 10 is a deciduous shrub of the genus Rosa, family Rosaceae, order Rosales, native to Asia. Also known as Togashi. The part used as the raw material for extraction is the fruit.

[0037] The Althaea officinalis used in Comparative Example 11 is a perennial plant of the Althaea genus, family Malvaceae, order Malvaceae, native to the Mediterranean coast of Europe. Also known as Marshmallow. The part used as the raw material for extraction is the root.

[0038] The allergen inactivator of the present invention may contain one of the plant extracts extracted from red maple and gambir as an active ingredient, or may contain a combination of the two as an active ingredient. When two plant extracts are combined to form an active ingredient, the blending ratio is not particularly limited and can be appropriately adjusted depending on the strength of the physiological activity of the plant extracts.

[0039] The allergen inactivating agent of the present invention may consist of only the plant extract, but may also be a formulation of the plant extract so that it can be applied to the skin, provided that the effect of the present invention is not impaired.

[0040] "External skin preparations" The topical skin preparation in the present invention refers to a preparation prepared by mixing an allergen inactivator with a medicine, quasi-drug, cosmetic, or the like.

[0041] The dosage form of the skin external preparation is not particularly limited as long as it does not impair the effect of the allergen inactivator, and can be any dosage form. The type of dosage form is not particularly limited, but examples thereof include semi-solids, liquids, or solids such as ointments, gels, creams, packs, patches, milky lotions, lotions, skin lotions, and powders.

[0042] The skin topical preparation of the present invention is not particularly limited as long as it does not impair the effect of the allergen inactivator, and additives that are usually used in the fields of medicines, quasi-drugs, cosmetics, etc. can be appropriately blended. The additives are not particularly limited, and examples thereof include purified water, oily components, surfactants, emulsifiers, lower alcohols, higher alcohols, polyhydric alcohols, water-soluble polymers, viscosity adjusters, gelling agents, moisturizers, bactericides, anti-inflammatory agents, analgesics, antifungal agents, keratin softening and peeling agents, skin colorants, hormones, ultraviolet absorbers, sweat deodorants, vitamins, blood flow promoters (vasodilators, blood circulation promoters), herbal medicines, pH adjusters, sequestering agents, pearlizing agents, natural fragrances, synthetic fragrances, dyes, pigments, antioxidants, preservatives, and perfume oils.

[0043] The amount of the allergen inactivator to be blended in the skin topical preparation of the present invention is not particularly limited, but the blending amount of the allergen inactivator is preferably 0.001 to 2.0 mass% based on the total mass of the skin topical preparation, more preferably 0.01 to 1.0 mass%, and even more preferably 0.01 to 0.5 mass%. If the blending amount of the allergen inactivator exceeds 2.0 mass%, the color will be impaired and the skin topical preparation will not be preferable. In addition, if it is less than 0.001 mass%, the effect of the allergen inactivator will not be fully exerted, and this will also not be preferable as a skin topical preparation.

[0044] The allergen inactivating agent incorporated in the topical skin preparation of the present invention may be either one of a red maple plant extract or a gambir tree plant extract incorporated as an allergen inactivating agent, or a combination of a red maple plant extract and a gambir tree plant extract may be incorporated as an allergen inactivating agent, and is not particularly limited.

[0045] When a plant extract of red maple and a plant extract of gambir are combined and incorporated into an external skin preparation as an allergen inactivating agent, the blending ratio of each plant extract is not particularly limited and may be any blending ratio.

[0046] The site of application of the topical skin preparation of the present invention is not particularly limited as long as it is applied to the skin, but it is preferably applied to the skin around mucous membranes such as the eyes, nasal cavity, and oral cavity.

[0047] When the skin topical preparation of the present invention is applied, the allergen adhering to the application site is inactivated by the allergen inactivator. Even if the inactivated allergen subsequently enters the body, it does not bind to antibodies and does not cause allergic symptoms. By applying the skin topical preparation of the present invention, even in an environment where allergens such as pollen are present, the total amount of allergens that cause allergic symptoms entering the human body can be reduced, and the allergic symptoms can be effectively alleviated. Therefore, it is preferable to apply the skin topical preparation of the present invention to the skin around the mucous membrane, which is the entry route of allergens. EXAMPLES

[0048] The present invention will be described in more detail below with reference to examples, but is not limited to these examples. In addition, a red maple was used as the plant of Example 1 of the present invention, and a gambir tree was used as the plant of Example 2 of the present invention. In addition, a Chinese tea was used as the plant of Comparative Example 1, a honeysuckle was used as the plant of Comparative Example 2, a crataeum was used as the plant of Comparative Example 3, a grape was used as the plant of Comparative Example 4, a fennel was used as the plant of Comparative Example 5, a sage was used as the plant of Comparative Example 6, a wild rose was used as the plant of Comparative Example 7, a Chinese yew was used as the plant of Comparative Example 8, an artemisia capillaris was used as the plant of Comparative Example 9, a Rosa rosa was used as the plant of Comparative Example 10, and a lavender was used as the plant of Comparative Example 11.

[0049] "Method for producing plant extracts as allergen inactivating agents" The used parts of each of Examples 1 and 2 and Comparative Examples 1 to 11 were dried, and 200 parts by weight of water were added to 10 parts by weight of this dried material, followed by extraction at 60°C for 5 hours, filtration, and distillation of the solvent to obtain each plant extract, which was used as an allergen inactivating agent.

[0050] "Manufacturing method for raw materials for skin care products" When the plant extract as an allergen inactivating agent is blended into the skin topical preparation, it is possible to blend the plant extract directly into the skin topical preparation, but it is preferable to blend the plant extract after processing so as not to cause precipitation in the skin topical preparation.Specific processing methods for preventing precipitation in the skin topical preparation include, for example, diluting or dissolving the plant extract in a specific solvent, storing it for a certain period of time, and confirming that no precipitation occurs, or removing the precipitate, and using the skin topical preparation raw material as the skin topical preparation, and blending the skin topical preparation raw material into the skin topical preparation.The amount of precipitation of precipitates, etc. changes depending on the selection of the solvent for diluting or dissolving the plant extract.Therefore, it is preferable to select a dilution concentration and dilution solvent that are less likely to cause precipitation for each plant extract.

[0051] For the above reasons, each plant extract was used to produce a skin topical preparation raw material. Specifically, 10 parts by mass of red maple extract was diluted with 90 parts by mass of glycerin to produce skin topical preparation raw material 1. 5 parts by mass of gambir extract was diluted with 95 parts by mass of a 50% by mass aqueous solution of 1,3-butylene glycol (hereinafter referred to as BG 50% by mass aqueous solution) to produce skin topical preparation raw material 2. 1 part by mass of tea extract was diluted with 99 parts by mass of a BG 50% by mass aqueous solution to produce skin topical preparation raw material 3. 1 part by mass of honeysuckle extract was diluted with 99 parts by mass of a BG 50% by mass aqueous solution to produce skin topical preparation raw material 4. 1 part by mass of hawthorn extract was diluted with 99 parts by mass of a BG 50% by mass aqueous solution to produce skin topical preparation raw material 5. 1 part by mass of grape extract was diluted with 99 parts by mass of a BG 50% by mass aqueous solution to produce skin topical preparation raw material 6. 0.5 parts by mass of fennel extract was diluted with 99.5 parts by mass of a 50% by mass BG aqueous solution to obtain a skin external preparation raw material 7. 1 part by mass of sage extract was diluted with 99 parts by mass of a 50% by mass BG aqueous solution to obtain a skin external preparation raw material 8. 1 part by mass of rose wild rose extract was diluted with 99 parts by mass of a 50% by mass BG aqueous solution to obtain a skin external preparation raw material 9. 2 parts by mass of chinese ginger extract was diluted with 98 parts by mass of a 50% by mass BG aqueous solution to obtain a skin external preparation raw material 10. 1 part by mass of artemisia capillaris extract was diluted with 99 parts by mass of a 50% by mass BG aqueous solution to obtain a skin external preparation raw material 11. 0.5 parts by mass of Rosa ricinus extract was diluted with 99.5 parts by mass of a 50% by mass BG aqueous solution to obtain a skin external preparation raw material 12. 1 part by mass of Vitis persica extract was diluted with 99 parts by mass of a 50% by mass BG aqueous solution to obtain a skin external preparation raw material 13.

[0052] "Measurement of the allergen inactivation effect of plant extracts" The allergen inactivation effect of the plant extract was measured by a cedar pollen allergen inactivation test, which measures the inactivation rate of cedar pollen allergen when the raw material for topical skin preparation is mixed with cedar pollen allergen. The test concentration was 2% by mass of the raw material for topical skin preparation, which is the amount that is actually expected to be mixed into the topical skin preparation.

[0053] (1) Cedar pollen allergen inactivation test Skin topical agent raw materials 1 to 13 were used as samples and diluted to a concentration of 2% by mass with PBS solution containing 0.1% bovine serum albumin to prepare sample dilution solutions 1 to 13. 100 μL of each of sample dilution solutions 1 to 13 was dispensed into each well of a 96-well microplate. Cedar pollen allergen (product name: purified cedar pollen antigen Cryj1, Bio Dynamics Research Institute Co., Ltd.) was dissolved in PBS solution containing 0.1% bovine serum albumin at a concentration of 2 ng / mL to prepare a cedar pollen allergen solution. 100 μL of the cedar pollen allergen solution was added to each well into which sample dilution solutions 1 to 13 were dispensed, and the wells were shaken at room temperature for 3 hours (sample-added cedar pollen allergen solutions 1 to 13). As a control, a solution in which 100 μL of cedar pollen allergen solution was added to 100 μL of PBS solution containing 0.1% bovine serum albumin was also shaken in the same manner (cedar pollen allergen solution with no sample added).

[0054] (2) Quantitative determination of cedar pollen allergen concentration (sandwich ELISA method) The cedar pollen allergen concentration (ng / mL) was measured using an ELISA kit (product name: cedar pollen antigen (Cryj1) measurement kit, manufactured by Nichi Nichi Pharmaceutical Co., Ltd.). 50 μL of each of the sample-added cedar pollen allergen solutions 1 to 13 that had been shaken for 3 hours was added to the antibody-coated plate, followed by the addition of a secondary antibody solution, and the reaction was allowed to proceed for 2 hours at 37°C. The reaction solution was then removed, and after washing three times, 100 μL of enzyme solution was added and the reaction was allowed to proceed for 1 hour at 37°C. After the reaction, the reaction solution was removed and washed six times, after which 100 μL of substrate solution was added to develop color, the reaction was stopped with a reaction stop solution, and the absorbance at 450 nm was measured using a microplate reader.

[0055] As a standard, cedar pollen allergen was dissolved in PBS solution containing 0.1% bovine serum albumin to prepare standard solutions for the calibration curve of 4ng / mL, 2ng / mL, 1ng / mL, 0.5ng / mL, and 0.25ng / mL. 50μL of the standard solutions for the calibration curve of each concentration were also measured using an ELISA kit (product name: cedar pollen antigen (Cryj1) measurement kit, manufactured by Nichi Nichi Pharmaceutical Co., Ltd.) in the same manner as above. A calibration curve was created from the absorbance of the standard solutions for the calibration curve.

[0056] The cedar pollen allergen concentrations of the sample-added cedar pollen allergen solutions 1 to 13 and the sample-free cedar pollen allergen solution were quantified using a calibration curve. Using the quantification results, the cedar pollen allergen inactivation rate (%) was calculated based on the following formula.

[0057] Cedar pollen allergen inactivation rate (%) = ((BA) / B) x 100 In the formula, A represents the "cedar pollen allergen concentration (ng / mL) in the cedar pollen allergen solution with added sample" and B represents the "cedar pollen allergen concentration (ng / mL) in the cedar pollen allergen solution with no added sample."

[0058] Table 1 shows the allergen inactivation rates (%) of plant extracts.

[0059] From the results shown in Table 1, it was confirmed that the plant extract derived from red maple (Example 1) and the plant extract derived from gambir tree (Example 2) have superior cedar pollen allergen inactivation activity compared to Comparative Examples 1 to 11. In particular, there was a large difference in inactivation rate depending on the plant species, with the allergen inactivation rates of Examples 1 and 2 being 50% or more, whereas the allergen inactivation rates of Comparative Examples 10 and 11 were 0%. This shows that there is a large difference in inactivation rate depending on the plant species.

[0060] Formulation examples of the present invention are given below. Each formulation example is prepared by a conventional method. <Formulation Example 1> Lotion 1 (Component name) (mass%) Skin care ingredient (Red maple) 0.01 Glycerin 5.0 1,3 Butylene Glycol 5.0 Trimethylglycine 3.0 Polyoxyethylene hydrogenated castor oil (60E.0) 0.5 Ethanol 2.0 Citric acid 0.1 Sodium citrate 0.1 Preservatives (appropriate amount) Purified water remainder

[0061] <Formulation Example 2> Lotion 2 (Component name) (mass%) Skin care ingredient (Gambir tree) 0.1 Glycerin 5.0 1,3 Butylene Glycol 5.0 Trimethylglycine 3.0 Polyoxyethylene hydrogenated castor oil (60E.0) 0.5 Ethanol 2.0 Citric acid 0.1 Sodium citrate 0.1 Preservatives and antioxidants (appropriate amount) Purified water remainder

[0062] <Formulation Example 3> Cosmetic cream 1 (Component name) (mass%) Skin care ingredient (Red maple) 0.1 Shea Butter 2.0 Jojoba oil 1.0 Stearyl alcohol 5.0 Squalane 10.0 Self-emulsifying glyceryl monostearate 3.0 Polyoxyethylene cetyl ether (20E.0) 1.0 1,3 Butylene Glycol 5.0 Glycerin 5.0 Sodium hydroxide 0.3 Fragrance 0.1 Preservatives and antioxidants (appropriate amount) Purified water remainder

[0063] <Formulation Example 4> Cosmetic Cream 2 (Component name) (mass%) Skin topical agent raw material (Gambir tree) 1.0 Shea Butter 2.0 Jojoba oil 1.0 Stearyl alcohol 5.0 Squalane 10.0 Self-emulsifying glyceryl monostearate 3.0 Polyoxyethylene cetyl ether (20E.0) 1.0 1,3 Butylene Glycol 5.0 Glycerin 5.0 Carboxyvinyl polymer 0.2 Fragrance 0.1 Sodium hydroxide 0.3 Preservatives and antioxidants (appropriate amount) Purified water remainder

[0064] <Formulation Example 5> Emulsion 1 (Component name) (mass%) Skin care ingredient (Red maple) 0.5 Squalane 5.0 Jojoba oil 0.3 Self-emulsifying glyceryl monostearate 1.0 Stearic acid 0.1 Carboxyvinyl polymer 0.1 Glycerin 1.5 Sodium hydroxide 0.3 Ethanol 7.0 Fragrance 0.1 Preservatives and antioxidants (appropriate amount) Purified water remainder

[0065] <Formulation Example 6> Emulsion 2 (Component name) (mass%) Skin care ingredient (Gambir tree) 0.5 Squalane 5.0 Jojoba oil 0.3 Self-emulsifying glyceryl monostearate 1.0 Stearic acid 0.1 Carboxyvinyl polymer 0.1 Glycerin 1.5 Sodium hydroxide 0.3 Ethanol 7.0 Fragrance 0.1 Preservatives and antioxidants (appropriate amount) Purified water remainder

[0066] <Formulation Example 7> Emulsion 3 (Component name) (mass%) Skin care ingredient (Red maple) 0.5 Skin care ingredient (Gambir tree) 0.5 Squalane 5.0 Jojoba oil 0.3 Self-emulsifying glyceryl monostearate 1.0 Stearic acid 0.1 Carboxyvinyl polymer 0.1 Glycerin 1.5 Sodium hydroxide 0.3 Ethanol 7.0 Fragrance 0.1 Preservatives and antioxidants (appropriate amount) Purified water remainder

[0067] <Prescription Example 8> Ointment (Component name) (mass%) Skin care ingredient (Red maple) 0.5 Skin care ingredient (Gambir tree) 0.5 Glycerin 2.0 Polyglyceryl-4 Oleate 0.5 Sodium hyaluronate 0.2 Stearyl glycyrrhizinate 0.05 Preservatives and antioxidants (appropriate amount) Vaseline Remaining

[0068] <Formulation example> Foundation (Component name) (mass%) Skin care ingredient (Red maple) 0.5 Skin care ingredient (Gambir tree) 0.5 Glyceryl stearate 1.0 Stearic acid 4.0 Behenyl Alcohol 1.0 Cetanol 0.5 Liquid Lanolin 2.0 Squalane 4.0 Hydrogenated Polydecene 4.0 Titanium dioxide 8.0 Talc 4.0 Bengala 1.0 Yellow iron oxide 0.5 Black iron oxide 0.2 Fragrance 0.1 Preservatives and antioxidants (appropriate amount) Purified water remainder

[0069] Although several embodiments of the present invention have been described above, these embodiments are presented as examples and are not intended to limit the scope of the invention. These embodiments can be implemented in various other forms, and various omissions, substitutions, and modifications can be made without departing from the gist of the invention. These embodiments and their omissions, substitutions, modifications, etc. are included in the scope and gist of the invention as well as the invention and its equivalents described in the claims.

[0070] [Table 1]

Claims

1. The present invention comprises an extract of one or two plants selected from the group consisting of red maple and gambier as active ingredients, The blending amount of the plant extract is 0.001 to 2.0% by mass, It is applied to the skin, An allergen inactivator that targets pollen.

2. The allergen inactivating agent described in claim 1, wherein the application site of the allergen inactivating agent is the skin surrounding a mucous membrane.

Citation Information

Patent Citations

  • Antiallergic drug

    JP1991258726A

  • Antiallergic agent and antiallergic cosmetic material and food containing the same

    JP1998036276A

  • Antiallergic drug containing plant extract

    JP1998053532A

  • Bradykinin antagonist comprising extract from rosaceae plant

    JP1999180880A

  • Scf binding inhibitor

    JP2002302451A